Scholarlink

Purpose <p>Graves’ orbitopathy (GO) is an autoimmune disease characterized by orbital inflammation, fibroblast activation, and adipogenesis, with limited effective therapies. This study aimed to investigate the role of biglycan (<i>BGN</i>) in GO pathogenesis and its underlying mechanisms.</p> Methods <p>Bioinformatic analyses were performed to identify differentially expressed genes in GO tissues. BGN protein levels were validated in orbital adipose tissues from GO patients. Functional effects of <i>BGN</i> were examined by overexpression or knockdown in human GO orbital fibroblasts (GO-OFs) in vitro. In vivo, a thyroid-associated ophthalmopathy (TAO) mouse model was used to evaluate the effects of <i>Bgn</i> knockdown on orbital fibrosis and adipogenesis.</p> Results <p>BGN expression was significantly upregulated in GO orbital tissues. In vitro, <i>BGN</i> overexpression promoted, while <i>BGN</i> knockdown attenuated, fibrosis and adipogenesis in GO-OFs. Mechanistically, <i>BGN</i> activated nuclear factor kappa B (NF-κB) and extracellular signal-regulated kinase (ERK) signaling pathways. In vivo, <i>Bgn</i> knockdown reduced GO-like pathological features, including fibrosis and adipose expansion, and decreased NF‑κB and ERK signaling activation.</p> Conclusion <p><i>BGN</i> contributes to fibrosis and adipogenesis in GO via NF‑κB and ERK signaling activation. These findings elucidate a pivotal role for <i>BGN</i> in GO pathogenesis and highlight its potential as a therapeutic target for GO treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biglycan knockdown improves Graves’ orbitopathy (GO)-like features via inhibiting NF-kB and ERK signaling

  • 期刊论文

  • 发表日期：

    2026年3月2日

查看全文
  • Changci Chenzhao,
  • Min Zhu,
  • Feng Zhang,
  • Bingyu Xie,
  • Jiamin Cao,
  • Wei Xiong,
  • Yao Tan

摘要

Purpose

Graves’ orbitopathy (GO) is an autoimmune disease characterized by orbital inflammation, fibroblast activation, and adipogenesis, with limited effective therapies. This study aimed to investigate the role of biglycan (BGN) in GO pathogenesis and its underlying mechanisms.

Methods

Bioinformatic analyses were performed to identify differentially expressed genes in GO tissues. BGN protein levels were validated in orbital adipose tissues from GO patients. Functional effects of BGN were examined by overexpression or knockdown in human GO orbital fibroblasts (GO-OFs) in vitro. In vivo, a thyroid-associated ophthalmopathy (TAO) mouse model was used to evaluate the effects of Bgn knockdown on orbital fibrosis and adipogenesis.

Results

BGN expression was significantly upregulated in GO orbital tissues. In vitro, BGN overexpression promoted, while BGN knockdown attenuated, fibrosis and adipogenesis in GO-OFs. Mechanistically, BGN activated nuclear factor kappa B (NF-κB) and extracellular signal-regulated kinase (ERK) signaling pathways. In vivo, Bgn knockdown reduced GO-like pathological features, including fibrosis and adipose expansion, and decreased NF‑κB and ERK signaling activation.

Conclusion

BGN contributes to fibrosis and adipogenesis in GO via NF‑κB and ERK signaling activation. These findings elucidate a pivotal role for BGN in GO pathogenesis and highlight its potential as a therapeutic target for GO treatment.